2 results
Approved WMOCompleted
To assess the immunomodulatory effects of erythromycin and clindamycin in healthy volunteers.
Approved WMOCompleted
The main objective of Study M15-722 is to characterize the efficacy, safety, and tolerability of ravagalimab (ABBV-323) as induction treatment in subjects with moderately to severely active UC.